Skip to main
ONCY
ONCY logo

ONCY Stock Forecast & Price Target

ONCY Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company that is developing pelareorep, an immunotherapeutic agent aimed at enhancing the immune system's ability to combat cancer, which could lead to significant advancements in treatment efficacy. The potential for strategic partnerships to accelerate the registration process for pelareorep may extend the company's operational timeline and unlock substantial shareholder value. Additionally, the external validation received from key opinion leaders enhances Oncolytics’ credibility in the industry, reinforcing the positive outlook for future growth and development of its product pipeline, including treatments for breast and gastrointestinal cancers.

Bears say

Oncolytics Biotech Inc. is still in the clinical stage and has yet to achieve significant commercial success, which raises concerns about its long-term viability and the sustainability of its financial health. The development of its lead candidate, pelareorep, and the other pipeline projects for various cancers carry high risks typical of early-stage biotechnology companies, such as potential delays in clinical trials and regulatory approvals that could hamper revenue generation. Additionally, the company’s reliance on funding from equity markets may expose it to dilution risks and could impact its financial stability if investor sentiment weakens.

ONCY has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oncolytics Biotech, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oncolytics Biotech, Inc. (ONCY) Forecast

Analysts have given ONCY a Strong Buy based on their latest research and market trends.

According to 4 analysts, ONCY has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oncolytics Biotech, Inc. (ONCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.